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Tumour development and progression involves a cascade of
genetic alterations (Fearon and Vogelstein, 1990; Knudson, 1993).
Techniques frequently used to study gene expression alterations,
such as RT-PCR, differential display PCR and Northern blot
analysis, have their limitations: some need large amounts of RNA,
others are time-consuming and can only study a small number of
genes simultaneously. With the development of the cDNA expres-
sion array technique, a method has become available to study the
expression levels of a large range of genes in one single hybridiza-
tion, requiring only a small amount of total RNA. Using this tech-
nique, a gene-expression fingerprint of every single tissue sample
can be made. Being a novel technique, no established methods for
interpreting the results are yet available. In recent publications
mostly two single hybridization experiments are compared and
differentially expressed genes are identified. Little attention is paid
to the method which is used to analyse the data (Shim et al, 1998;
Kaiser et al, 1999; Hoch et al, 1999). However, two research
groups have described methods to analyse the array data:
Hilsenbeck et al (1999) introduce a statistical method to compare
more than two hybridization experiments and to identify differen-
tially expressed genes, using a principal components analysis of
mean-centred log-transformed data. Rhee et al (1999) analyse
similarity in gene-expression patterns between three hybridization
experiments using scatterplots and ranktests.
Endometrial cancer is the most common gynaecologic malig-
nancy (Schottenfeld et al, 1995; Rose, 1996). In the majority of
cases, approximately 75%, the tumour is confined to the uterus at
time of diagnosis and has a relatively good prognosis. Patients
with advanced/recurrent disease have a poor prognosis, with
response rates to therapy of only 10–30% (Lentz, 1994; Rose,
1996). In general, tumour development and tumour progression
are thought to be driven by genetic alterations. Therefore, insight
into the molecular mechanisms involved in progression of
endometrial carcinoma is important when searching for new tools
to improve the outcome of patients with advanced/recurrent
endometrial carcinomas. Using the cDNA expressing array tech-
nique, gene-expression fingerprints of a variety of endometrial
carcinoma tissue samples can be produced, and differentially
expressed genes can be identified. We used the Atlas Human
Cancer Expression Array (Clontech, USA) on endometrial carci-
noma tissue and cell-line samples. The analysis method and the
results are evaluated in this article.
MATERIALS AND METHODS
Cell-lines
Ishikawa cells are derived from a human well differentiated
endometrial adenocarcinoma and were a generous gift from Dr
Masato Nishida (Tsukuba, Japan). ECC-1 cells are derived from a
well differentiated adenocarcinoma of human endometrium trans-
planted to nude mice and were a generous gift from Dr PG
Satyaswaroop (Hershey, USA). The T47D cells are derived from
well differentiated human breast cancer and were a generous gift
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from Dr B van der Burg (Utrecht, The Netherlands). All cells were
maintained in DMEM/F12 (Dulbecco’s modified Eagle’s
medium/Ham’s F12 (1:1 mix) with 15 mM Hepes, with L-gluta-
mine) supplemented with penicillin/streptomycin and in the pres-
ence of 7.5% fetal calf serum and 10–9 M oestradiol in a 37°C
incubator. For the experiments, cells were cultured to a 50%
confluency, medium was changed to DMEM/F12 supplemented
with 7.5% dextran-coated charcoal-treated fetal calf serum and
10–9 M oestradiol. Subsequently, cells were cultured for an other
72 h before harvesting. Total RNA was isolated as described
below.
Tissue samples
The endometrial carcinoma tissue samples were obtained from
patients attending hospital for treatment of endometrial cancer
(Department of Obstetrics and Gynaecology of the Academic
Hospital Rotterdam and Department of Obstetrics and
Gynaecology of the Sint Franscicus Hospital Rotterdam). The
histological typing and grade were established by the Department
of Pathology of the Academic Hospital Rotterdam according to the
modified FIGO staging system (Mikuta, 1993). The two human
endometrial carcinoma tissue samples used were tissue-sample
54: moderate well-differentiated (grade 2) endometrioid adeno-
carcinoma and tissue-sample 55: well-differentiated (grade 1)
endometrioid adenocarcinoma. The benign human endometrial
epithelial tissue sample was obtained from a patient attending the
Department of Obstetrics and Gynaecology of the Academic
Hospital Rotterdam for treatment of an uterus myomatosus (tissue-
sample 36). The endometrial epithelial samples were excised
directly after removal of the uterus from the body and frozen in
liquid nitrogen. Sandwich sections were made, by the Department
of Pathology of the Academic Hospital Rotterdam, to establish
percentage of tumour in the studied samples. The carcinoma
samples used in this study (samples 54 and 55) contained > 90%
endometrial carcinoma tissue, the benign endometrial tissue
sample (sample 36) contained > 90% benign endometrial epithe-
lial tissue.
RNA isolation
Total RNA was isolated from the cell-lines and the tissue specimen
following the instructions of the protocol PT3231-1, advised to use
in combination with the Atlas Human Cancer cDNA expression
array by Clontech Laboratories Inc. (Palo Alto, California, USA).
Atlas human cancer cDNA expression array
The Atlas human cancer cDNA expression array (7742–1) was
purchased from Clontech Laboratories Inc. Two identical nucleic
acid arrays were supplied containing 588 cancer-related human
cDNAs spotted as duplicates on nylon membranes. A list of the
genes spotted on the array, including array coordinates, is
available at Clontech’s web site (http://www.clontech.com).
cDNA synthesis and hybridization
Total RNA was reverse-transcribed into cDNA using a mixture of
array gene-specific primers and was labelled with 32P-dATP. Probe
purification and hybridization to the array were performed
following the array’s user manual. The array was exposed to a
phosphorimaging screen at room temperature for 24 h and scanned
using the PhosphorImager (Molecular Dynamics, Sunnyvale,
USA). The results were quantified using ImageQuant software
(Molecular Dynamics). A grid was applied to the image of the blot
to quantify the intensity of the hybridization of every spot.
Background signal was defined as the average of the hybridization
signals produced by the nine negative controls on the array. A gene
was defined to be expressed when the hybridization signal
extended to two times the background signal. According to the
Array manufacturer (Clontech Laboratories), the radioactive
cDNA signal is linear for RNAs present at levels of 0.01–3% of
the total RNA population. Saturation of the hybridization signal
was not observed.
Statistic analysis
The expression data obtained from PhosphorImager analysis were
logarithmic (10log) transformed. The xy-scatterplot displays the
expression levels of the genes for two compared experiments.
Every dot represents one of the genes on the cDNA array. The
x-value represents the 10log of the expression level of the gene in
one experiment, the y-value represents the 10log of the expression
level of the same gene in the other experiment. The xy-scatterplots
were produced using Microsoft Excel 97 software.
The least-squares regression line y = ax + b is the line with the
smallest sum of squared vertical distances between the points of
the xy-scatterplot and the line. The least-squared regression lines
were drawn using Microsoft Excel 97 software.
R-squared value is the Pearson correlation coefficient of the
least-squares regression line. The R-squared values were calcu-
lated using Microsoft Excel 97 software.
The standard deviation of the distance between the points and
the least-squared regression line was calculated using Microsoft
Excel 97 software. An area of standard deviation multiplied with
1.96 at both sides of the least-squared regression line was drawn in
the xy-scatter to establish a 95% prediction interval. Genes located
outside this area were identified as differentially expressed.
RESULTS
Using a cDNA expression array technique we established the
expression profile of 588 genes selected from different areas of
cancer research in two human endometrial carcinoma cell-lines
(Figure 1a and 1b), in two human endometrial carcinoma tissue
samples (Figure 1d), in one benign human endometrial tissue
sample (Figure 1c) and in one breast cancer cell-line. Using loga-
rithmic-transformed raw data, obtained from phosphorimager
analysis of cDNA expression array hybridization experiments, the
gene-expression fingerprints of the different tissue and cell-line
sample were compared. Using an xy-scatter plot, similarity in
gene-expression fingerprints between the cell-lines and tissue
samples was established and differentially expressed genes were
identified.
Normalization of the data
It seems that comparing gene-expressing fingerprints between
cell-lines or tissue samples should be conducted only after normal-
ization of the data for differences in background signal and for
differences in intensity of hybridization. The cancer cDNA expres-
sion array contains nine genes known as housekeeping genes (liver248 E Smid-Koopman et al
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glyceraldehyde 3-phosphate dehydrogenase, tubulin alpha, HLA
class 1 histocompatibility antigen C-4 a-chain, b-actin, 23-kDA
highly basic protein, ribosomal protein S9, ubiquitin, phospholi-
pase A2, HPRT). All these nine housekeeping genes, or a selection
of these genes, could be used as standards in normalization. When
using an xy-scatterplot and regression analysis, the raw data may be
analysed without the need for preceding normalization of the data.
In the least-squares regression line y = ax + b the slope value a can
be considered to represent the differences in hybridization intensity
and the intercept value b to represent the differences in background
signal. Expression level of the highest and lowest expressed genes
on the array varied extensively. Subsequently, when comparing
expression data, the differences between genes with high expres-
sion levels will have much greater impact than the differences
between low-expressed genes. Using a logarithmic transformation
of the raw data equalized these differences to some extent.
Figure 1 Gene-expression fingerprints of endometrial cells. Atlas human cancer cDNA expression array (Clontech, USA) was hybridized with 32P-labelled
cDNA probes obtained from total RNA of the Ishikawa endometrial carcinoma cell-line (A), the ECC-1 endometrial carcinoma cell-line (B), a benign human
endometrial tissue sample (benign tissue sample 36) (C) and a well differentiated human endometrial carcinoma tissue sample (tumour sample 54) (D). The
array contains 588 cancer-related human cDNAs spotted as duplicates. Nine housekeeping genes are spotted at the bottom line to serve as positive controls.
Dark grey spots at the outer end of the array represent genomic DNA spots, which serve as orientation marks. 1 = Cyclin D1, 2 = Decorin, 3 = TIMP3.
Table 1 R-squared values. Logarithmic transformed raw data were plotted in xy-scatter charts, regression analysis was performed and R-squared values were
calculated using Microsoft Excel 97 software
R-squared value Ishikawa 1 Ishikawa 2 ECC-1 T47D Benign Tumour Tumour
sample 36 sample 54 sample 55
Ishikawa 1 0.92 0.29 0.02 0.33 0.56 0.27
Ishikawa 2 0.92 nd nd nd nd nd
ECC-1 0.29 nd 0.33 0.22 0.26 0.42
T47D 0.02 nd 0.33 0.06 0.05 0.16
Benign sample 36 0.33 nd 0.22 0.06 0.74 0.41
Tumour sample 54 0.56 nd 0.26 0.05 0.74 0.47
Tumour sample 55 0.27 nd 0.42 0.16 0.41 0.47
n.d. = not determined
A B
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Reproducible gene-expression fingerprints
Total RNA was isolated from Ishikawa cells. The RNA sample
was divided in two batches, reverse-transcribed and the cDNA 
was labeled. The two labeled cDNA batches were hybridized 
to two twin membranes. A very high R2 = 0.92 was seen (Figure
2a), implying a high level of reproducibility of the cDNA 
array technique.
Identification of similarity
All the hybridization experiments were evaluated in pairs (Figure
2). R-squared values (= Pearson correlation coefficient) were
calculated. The R2-value represents the variation of data around
the least-squares regression line. Therefore the R2-value can be
considered as a quantification of similarity between compared
data. Table 1 gives a summary of the R2-values, which show
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Figure 2 Pair-wise comparison of gene-expression fingerprints using xy-scatterplot. A pair-wise comparison of the gene-expression fingerprint was made
between: the two Ishikawa cell hybridizations to the twin array membranes (A), the benign human endometrial tissue sample 36 and the human endometrial
carcinoma tissue sample 55 (B), the benign human endometrial tissue sample 36 and the human endometrial carcinoma tissue sample 54 (C), and between the
T47D breast cancer cells and the human endometrial carcinoma tissue sample 54 (D).
Table 2 Endometrial housekeeping genes and differentially expressed genes. Gene-expression was defined as a hybridization signal extending the value of
two times the background signal and is represented by ´.
Ishikawa ECC-1 Tumour Tumour Benign T47D
sample 55 sample 54 sample 36
Cyclin ´´´ ´´ –
CD 9 ´´´ ´´ –
GRB-2 isoform ´´´ ´´ –
c-myc binding protein ´´´ ´´ –
c-myc transcription factor (PUF) ´´´ ´´ –
BIGH-3 ´´´ ´´ –
Notch 2 ´´´ ´´ –
Hepatoma-derived growth factor ´´´ ´´ –
FAU ´´´ ´´ –
Cyclin D1; BCL-1 oncogene ´´´ –– ´
Decorin – – – – ´ –
TIMP3 – – – – ´ –
CD
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interesting trends. Comparing the benign endometrial tissue
sample with the two endometrial carcinoma tissue samples
resulted in R2 = 0,74 and R2 = 0.41 respectively. A higher degree of
similarity in the gene-expression fingerprint was found between
the endometrial samples (tissue and cell-line) (average R2 =
0.36 ± 0.13) than between the endometrial samples (tissue and
cell-line) and the breast cancer cell-line (average R2 = 0.12 ± 0.12),
implicating the existence of a tissue-specific gene-expression
fingerprint.
Specific gene expression
Using the xy-scatter plot and 95% prediction interval around the
least-squares regression line, differentially expressed genes were
identified. Comparing the benign endometrial tissue gene-expres-
sion fingerprint with the gene-expression fingerprints taken from
endometrial carcinoma tissue and cell-lines, three consistently
differentially expressed genes were identified (Table 2). TIMP3
and Decorin are down-regulated in all the carcinoma samples
(tissue samples and cell-lines), Cyclin D1 is up-regulated in the
carcinoma samples, except for the endometrial carcinoma tissue-
sample 54 (Figure 2b and 2c). These three genes may represent
important genes involved in the progression of endometrial carci-
nomas. Another group of genes, which showed expression at
similar levels in all endometrial samples, was identified (Table 2).
None of these genes was expressed in the human breast cancer
cell-line T47D. These genes seem to represent endometrial house-
keeping genes. Comparing the breast cancer cell-line T47D with
the endometrial carcinoma samples (tissue and cell-line) (Figure
2d) revealed too many differences (R2 = 0.12 ± 0.12, Table 1) in
gene-expression pattern, therefore identification of differential
expressed genes was not possible (see Discussion).
DISCUSSION
The expression level of all the 588 genes on the cDNA expression
array plus the 21 positive and negative control dots were used in
the analysis. The majority of the gene-expression level signals did
not exceed two times the background hybridization signal level
(Figure 1). In the xy-scatterplot the least-squares regression line
will be highly determined by these signal levels. As long as a high
degree of similarity exists between the expression pattern of the
array experiments, the slope value a (in the least-squares regres-
sion line y = ax + b) can be considered to represent the differences
in hybridization intensity and the intercept value b to represent the
differences in background signal. Therefore, raw data obtained
from cDNA expression array hybridization experiments can be
analysed without the need of preceding normalization of the data
(Figure 2a–c). In the same instance, differentially expressed
genes can be identified using a 95% prediction interval around the
least-squares regression line. The R2-value of the least-squares
regression line quantifies the degree of similarity. However, when
little similarity exists between the compared expression patterns,
resulting in a low R2-value, the least-squares regression line will
be almost random. An example of this situation is seen in the
comparison between the gene-expression fingerprint of the T47D
cell-line and the endometrial carcinoma tissue sample (Figure 2d).
Differentially expressed genes cannot be identified in this case.
The lowest R2-value at which the least-squares regression line and
95% prediction interval around the regression line can be used to
identify differentially expressed genes has yet to be established.
A higher degree of resemblance exists between the endometrial
samples (tissue and cell-line samples), than between the endome-
trial samples and the breast cancer cell-line, implicating a basic
endometrial gene-expression fingerprint. As tumour behaviour is
thought to be driven by genetic alterations, it is plausible that clin-
ical behaviour of carcinomas can be reflected in their specific
gene-expression fingerprints (Blok et al, 1995; 1999; Chang et al,
1997). Taking this one step further, a database could be
constructed containing gene-expression fingerprints of various
endometrial carcinoma tissue samples of different clinical stage,
different histological grade and different progesterone and
oestrogen receptor status linked to information on clinical follow-
up. Comparing the gene-expression fingerprint of an uncharacter-
ized tumour sample of interest with the database could reveal the
potential clinical behaviour of the uncharacterized tumour. A table
of R2-values, as shown in Figure 2, could be used to establish the
degree of similarity between the tumour samples. Using the cDNA
expression array to reveal degrees of similarity between uncharac-
terized tumour samples of interest and tumour samples of known
clinical behaviour, could have great potential value in the diag-
nosis and prognosis of endometrial cancer. However, to confirm
the potential value of the cDNA arrays as a diagnostic and prog-
nostic tool, a gene-expression fingerprint database of a large group
of fully characterized endometrial carcinoma tissue samples
should be constructed and analysed. The current investigation may
provide a practical and useful method to analyse these data.
Comparing gene-expression fingerprints of different tumour
samples will also identify differentially expressed genes. Using the
xy-scatterplot analysis and the 95% prediction interval around the
least-squares regression line, three genes (Decorin, TIMP3 and
Cyclin D1) were identified to be differentially expressed between
benign endometrial cells and endometrial carcinoma cells. Decorin
(small leucin-rich protoglycan) inhibits TGFb and induces p21,
resulting in inhibition of proliferation (Stander et al, 1999; Iozzo et
al, 1999). TIMP3 (tissue inhibitor of metaloproteinase number 3)
inhibits the matrix metaloproteinases MMPs. Excess of MMPs
stimulates tumour invasion and metastasis (Kugler, 1999; Sato et
al, 1992). Cyclin D1 initiates the G1-S phase progression (Chen et
al, 1998). Oestrogens are found to induce nuclear localization of
Cyclin D1 in endometrial cells, resulting in increased cell prolifer-
ation (Tong and Pollard, 1999). In breast cancers Cyclin D1 can
act as an oncogene (Russell et al, 1999) and is found to act as a
CDK-independent activator of the oestrogen receptor in breast
epithelial cells (Zwijsen et al, 1997). The loss of Decorin and
TIMP3 expression and the gain of Cyclin D1 expression in the
endometrial carcinoma cell-lines and tissue samples could indicate
an important role of Decorin, TIMP3 and Cyclin D1 in the devel-
opment and progression of endometrial cancer. However, the
number of samples analysed is too small to draw conclusions.
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